Introduction
============

Cardiovascular diseases are the leading causes of mortality worldwide and account for over 40% of all deaths in People's Republic of China.[@b1-cia-10-1467] In the past years, traditional risk factors contributing to a coronary heart disease event have been recognized and treated.[@b2-cia-10-1467] However, despite predictive strategies, a great number of coronary heart disease cases remain unpredicted. Novel markers which can either anticipate or be associated with an incident coronary heart disease event have been introduced in recent decades.[@b3-cia-10-1467] Homocysteine (Hcy) is one of them.[@b4-cia-10-1467] Hcy is a nonessential amino acid that is known as a marker of endothelial injury.[@b5-cia-10-1467] Elevated total Hcy is known to be able to increase oxidative stress, diminish vasodilation, stimulate the proliferation of vascular smooth muscle cells, alter the elastic properties of the vascular wall, and thus increase the risk for atherosclerosis.[@b6-cia-10-1467],[@b7-cia-10-1467] There is a positive association between total Hcy and coronary heart disease[@b8-cia-10-1467]--[@b10-cia-10-1467] in general population of both People's Republic of China and other countries.

The proportion of older population especially for octogenarians (age \>80 years) increase quickly, and will grow to more than one in 12 by the year 2050.[@b11-cia-10-1467] The increasing prevalence of coronary heart disease is associated with aging. Coronary angiography showed that the lesions of elderly patients were more complex, and the older patients presented higher comorbidity, poorer clinical outcomes, and higher all-cause mortality, compared with younger patients. The association of Hcy level with cardiovascular disease appears to be particularly strong in the very old, and Hcy level has even been shown to be a better predictor of cardiovascular mortality in this age group than models based on classic Framingham risk factors.[@b12-cia-10-1467]

However, the association between the level of Hcy and the stenosis of coronary artery, and the prognostic value of Hcy in long-term clinical outcomes are unclear, especially in octogenarians. The purpose of this study was to investigate the association between plasma Hcy and all-cause mortality, and long-term prognostic impact of plasma Hcy on Chinese acute coronary syndrome (ACS) octogenarians.

Methods
=======

Study population
----------------

This single center study comprised 660 consecutive ACS patients (age \>80 years) who had a complete clinical history of ACS, which was defined as unstable angina pectoris, non-ST-segment elevated myocardial infarction (MI) or ST-segment elevated MI,[@b13-cia-10-1467] and who were admitted to our hospital and underwent coronary angiography from January 2006 to December 2011. All patients consented in writing to their participation in the study. The study complied with the declaration of Helsinki for investigation in human beings and was approved by the institutional ethics committee of the Chinese People's Liberation Army General Hospital.

Data collection
---------------

On admission, every patient's demographic characteristics, cardiovascular risk factors (such as diabetes, primary hypertension, hyperlipidemia, previous MI, previous stroke, chronic renal failure \[CRF\], and smoking), vital signs, information on laboratory data and examinations, cardiovascular medication were collected. Renal function was assessed using the baseline estimated glomerular filtration rate (eGFR). Impaired renal function was defined as an eGFR \<60 mL/min/1.73 m^2^.[@b14-cia-10-1467],[@b15-cia-10-1467]

Definitions
-----------

Hypercholesterolemia was defined as fasting serum total cholesterol level \>5.5 mmol/L or use of lipid-lowering therapy at the time of the procedure. Hypertension was defined as blood pressure \>140/90 mmHg or the use of antihypertensive medications. MI was diagnosed by raised creatine kinase MB greater than three times the upper limit of normal value. Diabetes mellitus was defined as hyperglycemia, requiring antidiabetic drugs or fasting blood sugar \>7.0 mmol/L.

Coronary angiography
--------------------

After admission, all patients underwent coronary angiography. An obstructive lesion causing ≥50% reduction of lumen diameter in at least one of the coronary arteries was defined as coronary artery disease (CAD). The lesion characteristics of coronary artery were recorded. The severity of coronary artery was calculated by Gensini score.[@b16-cia-10-1467] The percutaneous coronary intervention (PCI) procedures were recorded.

Population grouping and follow-up
---------------------------------

Our patients were divided into three groups according to Hcy tertiles. Regular follow-up was performed for all patients at a 6-month interval. Long-term clinical major adverse cardiac events (MACE), including all-cause death, MI, and repeat revascularization (repeat PCI or coronary artery bypass grafting), were collected and compared between the three groups.

Statistical analysis
--------------------

Statistical analysis was performed using the Statistical Package for the Social Sciences, version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables including age, heart rate, body mass index (BMI), blood pressure, eject fraction (EF), and laboratory data were expressed as the mean ± standard deviation or median (with inter-quartile range). The Student's *t*-test was used if continuous variables were normally distributed, while the Wilcoxon two-sample test was used if continuous variables (such as Gensini score, C-reactive protein \[CRP\]) were not normally distributed. Categorical data were summarized as frequency. The chi-square test was used to compare categorical variables including sex, risk factors, ACS type, and medication. Correlation between plasma Hcy level and blood biochemistry indicators were performed using the Pearson correlation model. Survival rates of three groups were calculated according to the Kaplan--Meier method. Differences between survival curves of high plasma level of Hcy (H-Hcy), middle plasma level of Hcy (M-Hcy), and low plasma level of Hcy (L-Hcy) groups were tested by the log-rank test. A Cox proportional hazards model was used to identify predictors of all-cause mortality in ACS octogenarians. Odds ratios (ORs) were reported with corresponding 95% confidence intervals (CIs). The respective predictive cutoff values were constructed according to the receiver operating characteristic curves for Hcy for discrimination between surviving and dead patients. The areas under the curve were compared using Hanley and McNeil method, and the predictive cutoff value of Hcy for mortality was evaluated. All *P*-values were two-sided, and a *P*-value \<0.05 was considered statistically significant.

Results
=======

Baseline characteristics of patients
------------------------------------

The baseline clinical characteristics of 621 (621/660, 94.09%) enrolled patients, who fulfilled the follow-up, were collected. Thirty-nine patients were lost during the follow-up because of wrong telephone number. Of the 621 patients, there were 451 men and 170 women. Patients were classified into three groups according to Hcy tertiles (\<13.20 μmol/L, 13.21--18.28 μmol/L, and \>18.29 μmol/L). The baseline clinical characteristics, medication, and treatment strategies of the three groups were shown in [Table 1](#t1-cia-10-1467){ref-type="table"}.

As compared with those in low (L-Hcy) and middle (M-Hcy) plasma level of Hcy groups, patients in H-Hcy group had higher diastolic blood pressure (DBP) and higher ratio of male (*P*\<0.05), while there was no difference between other characteristics including age, heart rate, BMI, systolic blood pressure (SBP), EF, and Gensini score (*P*\>0.05) ([Figure 1](#f1-cia-10-1467){ref-type="fig"}). The ratios of CRF and history of MI were higher in H-Hcy group than in L-Hcy and M-Hcy groups (*P*\<0.05). Among blood biochemistry indicators, plasma cystatin C (Cys C), uric acid (UA), and CRP concentrations were higher and eGFR level was lower in H-Hcy group than in L-Hcy and M-Hcy groups (*P*=0.001). In addition, no difference was found in medication use and treatment strategies between the three groups. No difference was found in ACS type (*P*\>0.05).

The distribution characteristics of lesions were similar between the three groups, and there was no significant difference between the three groups as to multivessel disease or number and distribution of target vessels. Stent implantations, including multistents and number of stents, were almost equal to one another (shown in [Table 2](#t2-cia-10-1467){ref-type="table"}).

The correlation between Hcy and blood biochemistry indicators
-------------------------------------------------------------

The UA level and Cys C level increased and eGFR level decreased with Hcy level (*P*\<0.01). Further analysis indicated the Hcy level was positively correlated with UA level (*r*=0.211, *P*=0.001) and Cys C level (*r*=0.212, *P*=0.001), was negatively correlated with eGFR (*r*=−0.148, *P*=0.018).

Long-term outcomes
------------------

The duration of the follow-up was from 13 to 79 months (median, 28 months; inter-quartile range, 16--38 months). During the follow-up period, 18 patients (8.69%) died and 16 patients (7.73%) experienced reinfarction or revascularization in L-Hcy group, and the rate of MACE was 16.42%. Twenty-one patients (10.14%) died and ten patients (4.83%) experienced reinfarction or revascularization in M-Hcy group, and the rate of MACE was 14.97%. Forty-five patients (28.51%) died and 14 patients (6.76%) experienced reinfarction or revascularization in H-Hcy group, and the rate of MACE was 28.51%. The all-cause mortality and MACE rate in H-Hcy group were higher than those in L-Hcy and M-Hcy groups (*P*=0.0001, *P*=0.0008). However, there were no significant difference in the reinfarction and revascularization rates between the three groups (*P*=0.473) ([Figure 2](#f2-cia-10-1467){ref-type="fig"}).

[Figure 3](#f3-cia-10-1467){ref-type="fig"} shows the Kaplan--Meier survival curves for all-cause death according to Hcy tertiles. The cumulative survival rate of H-Hcy group was significantly lower than that of L-Hcy and M-Hcy groups in the long term (*P*=0.006). H-Hcy group had a high risk of all-cause death.

Risk factors associated with mortality during follow-up
-------------------------------------------------------

A Cox regression analysis was performed to determine the factors that were associated with all-cause death at the end of the follow-up. After being adjusted for general conditions including age, sex, heart rate, BMI, SBP and DBP, and EF, risk factors including diabetes mellitus, hypertension, hyperlipidemia, previous MI, stroke, and CRF, and blood biochemistry indicators including triglyceride, total cholesterol, low density lipoprotein-C, and fasting blood glucose, plasma Hcy concentration (OR=2.26, 95% CI=1.23--4.16, *P*=0.023) and Cys C concentration (OR=2.89, 95% CI=1.35--6.16, *P*=0.006) were the independent predictors for long-term mortality, plasma Hcy concentration (OR=1.91, 95% CI=1.03--3.51, *P*=0.039) and history of MI (OR=2.27, 95% CI=1.16--4.45, *P*=0.017) were the independent predictors for MACE.

Diagnostic power of Hcy for long-term mortality during follow-up
----------------------------------------------------------------

The respective predictive cutoff values were constructed according to the receiver operating characteristic curves for Hcy for discrimination between surviving and dead patients ([Figure 4](#f4-cia-10-1467){ref-type="fig"}). The area under the curve was 0.710 (0.585, 0.796, *P*=0.001). The predictive cutoff value of Hcy for mortality was 17.67 μmol/L (sensitivity 0.667, specificity 0.681).

Discussion
==========

In the present study, we have found that plasma Hcy concentration was an independent predictor for long-term mortality and MACE in ACS octogenarians after controlling conventional cardiovascular risk factors. Our study evaluated the effects of Hcy level on the clinical characters and coronary artery stenosis in ACS octogenarians for the first time, and showed a positive association between plasma Hcy level and Cys C and UA level, a negative association between plasma Hcy level and eGFR. The ratios of male, MI and CRF were higher in H-Hcy group. However, there was no relation between the coronary artery stenosis degree and Hcy level.

Hcy levels suggest a contribution of Hcy to cardiovascular diseases.[@b17-cia-10-1467] H-Hcy are independently associated with the prevalence and extent of CAD.[@b18-cia-10-1467],[@b19-cia-10-1467] Hcy-lowering interventions should be used for preventing cardiovascular events occurrence.[@b20-cia-10-1467] Although the association of Hcy level with cardiovascular disease appears to be particularly strong in the very old population and Hcy level has even been shown to be a better predictor of cardiovascular mortality in this age group than models based on classic Framingham risk factors,[@b12-cia-10-1467] and elevated plasma total Hcy level was related to 30-day cardiovascular events in patients with acute myocardial infarction (AMI),[@b21-cia-10-1467] there is still no consistent opinion about the relation between the Hcy level and long-term outcomes of coronary heart disease, especially for octogenarian ACS patients. In this study, the Hcy-ACS association in the octogenarian was independent of a number of risk factors, and the diagnostic power of Hcy for mortality was identified for the first time.

However, there were still some controversy opinions about the benefits from the treatments of folic acid and Hcy lowering. Some papers showed that folic acid and B vitamins treatments, despite significant Hcy lowering, did not reduce a combined end point of total cardiovascular events among high-risk women[@b22-cia-10-1467] and the risk of recurrent cardiovascular disease after acute MI.[@b23-cia-10-1467] These were not conflict with the conclusion of our research. First, the enrolled populations were different, our study was comprised of very old ACS patients, and other study was comprised of 60-years-old high-risk women; second, our result indicated the higher level of Hcy, the poorer prognosis, and we did not evaluate the lowering of plasma Hcy level with the prognosis.

The octogenarian ACS is a special population, accompanied with more traditional and novel risk factors and presenting more complex lesions, higher comorbidity, poorer clinical outcomes, and higher mortality. Few clinical researches were conducted on the risk factors of the prognosis in the very old ACS patients. Our earlier studies indicated that Gensini score was an independent predictor of long-term mortality in ACS octogenarians,[@b24-cia-10-1467] and plasma Cys C level was an independent predictor for long-term mortality in ACS octogenarians with diabetes mellitus.[@b25-cia-10-1467] In the present study, we performed a Cox regression analysis and adjusted general conditions and clinical risk factors, and showed the plasma elevated Hcy was an independent predictor for long-term mortality and MACE for octogenarian ACS.

In the present study, we found that the Hcy level was positively correlated with Cys C level (*r*=0.212, *P*=0.001) and UA level (*r*=0.211, *P*=0.001) in ACS octogenarians. These were consistent with some previous researches. As a member of the cysteine protease inhibitor superfamily, Cys C is synthesized by various nucleated cells and involved in the metabolism of Hcy. Cys C can inhibit Hcy degradation and increase serum Hcy level. Cys C could be a useful laboratory biochemical marker in predicting the severity of CAD and was associated with biochemical atherosclerosis markers Hcy.[@b26-cia-10-1467] In patients with CAD, elevated Hcy was directly related to serum UA (*P*\<0.001).[@b27-cia-10-1467] Hyperhomocysteinemia had an OR for hyperuricemia of 1.7 for males and a significant association with hyperuricemia in screening subjects. The combined effect of these two factors accelerated atherosclerosis.[@b28-cia-10-1467]

Currently, the precise mechanism of hyperhomocysteinemia on the risk of coronary heart disease is not clear even for the prognosis, especially for the very old ACS patients. Hyperhomocysteinemia increased carotid intima-media thickness[@b29-cia-10-1467] and as a prothrombotic factor, was related with platelet reactivity, which may be a possibly new challenge of aspirin therapy.[@b30-cia-10-1467] Hcy increased arterial stiffness[@b31-cia-10-1467] and impaired coronary artery endothelial function by increased increasing insulin resistance.[@b32-cia-10-1467]

In this study, we analyzed the relative indicators, and found no significant difference between H-Hcy group and L-Hcy group in fasting blood glucose, platelet, SBP and DBP. We found that CRP and Cys C were higher in H-Hcy group than in L-Hcy group. Our early study showed that CRP and Cys C were positively related in the very old ACS patients with diabetes mellitus. So we deduce that, in our study patients, H-Hcy may be accompanied with Cys C, promote the inflammatory reaction, and accelerate the prognosis.

Some limitations in interpretation of our study results should be kept in mind. Our study was a single center registry, so it offered observational data on nonrandomized patients. In addition, plasma Hcy level was measured on admission for a single point in the present study. As we did not know the serum Hcy levels during follow-up of 2 years, we were not able to consider this valuable information in our analysis.

Conclusion
==========

All-cause mortality and MACE of ACS octogenarians increased with the level of plasma Hcy. Hyperhomocysteinemia was an important predictor for long-term mortality and MACE of ACS octogenarians. The predictive cut off value of Hcy for mortality was 17.67 μmol/L.
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![The all-cause mortality and MACE rates in three groups (*P*=0.0001, *P*=0.0008).\
**Abbreviation:** MACE, major adverse cardiac events.](cia-10-1467Fig2){#f2-cia-10-1467}

![Kaplan--Meier survival rate curve for all-cause death according to Hcy tertiles (*P*=0.006).\
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![ROC curves for Hcy for discrimination between surviving and dead patients.\
**Notes:** The AUC was 0.710 (*P*=0.001). The predictive cut-off value of Hcy for mortality was 17.67 μmol/L (sensitivity 0.667, specificity 0.681).\
**Abbreviations:** AUC, area under the curve; Hcy, homocysteine; ROC, receiver operating characteristic.](cia-10-1467Fig4){#f4-cia-10-1467}

###### 

Study population clinical characteristics in ACS octogenarians according to homocysteine tertiles

  -------------------------------------------------------------------------------------------------------------
  Characteristic (n)          Group 1 \<13.20\       Group 2 13.21--18.28\   Group 3 \>18.29\       *P*-value
                              nmol/L (n=207)         nmol/L (n=207)          nmol/L (n=207)         
  --------------------------- ---------------------- ----------------------- ---------------------- -----------
  General conditions                                                                                

   Age (years)                81.63±2.04             81.63±1.81              81.99±2.26             0.368

   Male                       145                    140                     166                    **0.026**

   HR (bpm)                   74.02±12.19            76.12±12.19             73.49±12.78            0.074

   BMI (kg/m^2^)              24.68±2.93             24.34±3.40              24.45±3.40             0.758

   SBP (mmHg)                 136.90±17.70           140.02±22.37            137.91±19.19           0.548

   DBP (mmHg)                 70.54±12.50            69.54±11.33             74.60.62±11.96         **0.010**

   EF (%)                     55.40±9.90             57.44±8.97              56.09±8.47             0.320

  Gensini score               48 (IQR 22--80)        39 (IQR 17.5--73)       40 (IQR 16--56)        0.218

  Risk factors                                                                                      

   Hypertension               169                    162                     148                    **0.044**

   DM                         87                     65                      71                     0.066

   Hyperlipidemia             45                     51                      47                     0.775

   Previous MI                33                     30                      53                     **0.007**

   Previous stroke            37                     47                      42                     0.474

   CRF                        16                     16                      43                     **0.000**

   Smoking                    44                     49                      57                     0.322

  Baseline blood feature                                                                            

   TC (mmol/L)                3.85±1.11              4.03±1.16               3.96±1.01              0.512

   TG (mmol/L)                1.48±0.98              1.62±1.30               1.39±0.64              0.290

   HDL-C (mmol/L)             1.15±0.48              1.22±0.36               1.14±0.40              0.362

   LDL-C (mmol/L)             2.21±0.87              2.38±0.98               2.24±0.81              0.375

   FBG (mmol/L)               6.01±1.74              6.33±2.91               6.30±2.11              0.601

   UA (μmol/L)                333.6±87.75            354.1±99.1              392.4±101.9            **0.000**

   eGFR (mL/min/1.73 m^2^)    75.13±18.46            78.42±45.5              63.17±18.16            **0.002**

   Cys C (mg/L)               1.45±0.49              1.41±0.39               1.75±0.60              **0.001**

   PLT(×10^9^)                131±28                 142±35                  138±41                 0.347

   CRP (mg/dL)                0.16 (IQR 0.1--0.47)   0.20 (IQR 0.1--0.35)    0.38 (IQR 0.1--0.65)   **0.031**

  ACS type                                                                                          0.887

   STEMI                      23                     25                      28                     

   NSTEMI                     18                     22                      21                     

   UAP                        166                    160                     158                    

  Cardiovascular medication                                                                         

   Aspirin                    204                    202                     197                    0.107

   Clopidogrel                195                    202                     195                    0.169

   Beta-blocker               132                    131                     130                    0.979

   ACEI/ARB                   122                    132                     113                    0.164

   Statin                     194                    195                     185                    0.123

  Treatment strategy                                                                                

   PCI                        134                    135                     145                    0.447

   CABG                       8                      7                       11                     0594

   Intensive medicine         65                     65                      51                     0.217
  -------------------------------------------------------------------------------------------------------------

**Notes:** Data are shown as mean ± standard deviation or n. Data in bold indicates *P*-values \<0.05.

**Abbreviations:** ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CRF, chronic renal failure; CRP, C-reactive protein; Cys C, cystatin C; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, eject fraction; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HDL-C, high density lipoprotein-C; HR, heart rate; IQR, inter-quartile range; LDL-C, low density lipoprotein-C; MI, myocardial infarction; NSTEMI, non-ST-segment elevated myocardial infarction; PCI, percutaneous coronary angiography; PLT, platelet; SBP, systolic blood pressure; STEMI, ST-segment elevated myocardial infarction; TC, total cholesterol; TG, triglyceride; UA, uric acid; UAP, unstable angina pectoris.

###### 

Coronary artery characteristics and PCI treatment in ACS octogenarians

  Characteristic (n)               Group 1 \<13.20 nmol/L (n=207)   Group 2 13.21--18.28 nmol/L (n=207)   Group 3 \>18.29 nmol/L (n=207)   *P*-value
  -------------------------------- -------------------------------- ------------------------------------- -------------------------------- -----------
  **Number of diseased vessels**                                                                                                           
  Lesions                                                                                                                                  
   LM                              35                               24                                    22                               0.124
   LAD                             159                              167                                   157                              0.520
   LCX                             107                              98                                    88                               0.174
   RCA                             120                              109                                   115                              0.553
   Multivessel disease             146                              141                                   133                              0.423
  **PCI**                                                                                                                                  
   Target vessels                                                                                                                          
   LM                              17                               11                                    10                               0.299
   LAD                             65                               80                                    68                               0.259
   LCX                             39                               31                                    27                               0.257
   RCA                             45                               54                                    43                               0.391
   Multilesion stenting            76                               71                                    58                               0.152
   Number of stents (Mean±SD)      2.02±1.01                        1.96±1.02                             1.79±1.05                        0.062

**Abbreviations:** ACS, acute coronary syndrome; LAD, left anterior descending; LCX, left circumflex; LM, left main; PCI, percutaneous coronary intervention; RCA, right coronary artery; SD, standard deviation.
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